Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution in Patients With Autoimmune Pulmonary Alveolar Proteinosis
SVRA Stock | USD 3.31 0.05 1.49% |
About 61% of Savara's investor base is looking to short. The analysis of the overall investor sentiment regarding Savara Inc suggests that many traders are alarmed. The current market sentiment, together with Savara's historical and current headlines, can help investors time the market. In addition, many technical investors use Savara Inc stock news signals to limit their universe of possible portfolio assets.
Savara |
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it wil
Read at businesswire.com
Savara Fundamental Analysis
We analyze Savara's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Savara using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Savara based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Savara is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Savara Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Savara stock to make a market-neutral strategy. Peer analysis of Savara could also be used in its relative valuation, which is a method of valuing Savara by comparing valuation metrics with similar companies.
Peers
Savara Related Equities
ALXO | Alx Oncology | 12.16 | ||||
ACLX | Arcellx | 8.69 | ||||
FENC | Fennec Pharmaceuticals | 2.97 | ||||
GPCR | Structure Therapeutics | 2.38 | ||||
TRDA | Entrada Therapeutics | 2.16 | ||||
RZLT | Rezolute | 1.19 | ||||
AVTE | Aerovate Therapeutics | 1.14 | ||||
XOMAO | XOMA | 0.39 | ||||
CRNX | Crinetics Pharmaceuticals | 0.33 | ||||
LBPH | Longboard Pharmaceuticals | 0.02 | ||||
STOK | Stoke Therapeutics | 0.33 | ||||
KZR | Kezar Life | 0.80 | ||||
TPST | Tempest Therapeutics | 1.04 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
ANAB | AnaptysBio | 2.32 | ||||
XOMA | XOMA Corp | 3.05 | ||||
DYN | Dyne Therapeutics | 4.34 | ||||
EWTX | Edgewise Therapeutics | 4.42 | ||||
XLO | Xilio Development | 4.59 | ||||
SRRK | Scholar Rock | 4.86 | ||||
RVMD | Revolution Medicines | 10.46 | ||||
TARA | Protara Therapeutics | 15.95 | ||||
PTIX | Protagenic Therapeutics | 20.34 |
Complementary Tools for Savara Stock analysis
When running Savara's price analysis, check to measure Savara's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Savara is operating at the current time. Most of Savara's value examination focuses on studying past and present price action to predict the probability of Savara's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Savara's price. Additionally, you may evaluate how the addition of Savara to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |